// App-Quantinova.ai

P5-14-06 : Lapatinib reverses endocrine resistance in select patients with HER2 negative, hormone positive metastatic breast cancer

Researchers

Presenter

  • Sharma P

Principal Investigators

  • Kimler BF

  • Ward C

  • Godwin AK

  • Khan QJ

  • Wang K

  • Ali S

  • Balasubramanian S

  • Dea AP

  • Madhusudhana S

  • Baccaray S

  • Fabian CJ

  • Schmitt SB

Medical Centers

  • Foundation Medicine, Inc, Cambridge, MA

  • University of Kansas Medical Center, Kansas City, MO

  • Hays Medical Center, Hays, Kansas

  • VA Medical Center, Kansas City, MO.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Ecdysoneless

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Fulvestrant

  • Lapatinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved